¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02
±³À°ÀÏÀÚ : 2022-10-02
±³À°Àå¼Ò : ¾Ú¹è¼­´õ ¼­¿ï Ç®¸¸ È£ÅÚ ±×·£µåº¼·ë 2F  
±³À°ÁÖÁ¦ : 2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ  
´ã´çÀÚ : ÃÖ°æ¼ö
¿¬¶ôó : 02-2038-7674  
À̸ÞÀÏ : gschoi@humming.co.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í Á¤È¸¿ø4¸¸¿ø,Æò»ýȸ¿ø2¸¸¿ø,Àü°øÀÇ1¸¸¿ø,ºñȸ¿ø20¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:30~09:40 Antipruritic effect of synthetic TRPM8 channel agonist (cryosim-1) gel on histaminergic and non-histaminergic itch in healthy human skin: a single-blind, randomized vehicle-controlled study  À̼ҿ¬(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:40~09:50 Long-Term Efficacy of Dupilumab in South Korean Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Open-Label Extension Trial  ³ëÀ±Áø(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 09:50~10:00 Interferon-¥ã inducible protein 10 promotes Th2 inflammation by activating IL-4-secreting Th2 cells, exacerbating mite allergen-sensitized atopic dermatitis  ¹æÁø¼±(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:00~10:10 ASSOCIATION BETWEEN METABOLIC SYNDROME AND ATOPIC DISEASES INCLUDING ATOPIC DERMATITIS, ALLERGIC RHINITIS AND ASTHMA  ±Ç¹ÎÁ¤(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:10~10:35 Interpretations of research data for atopic dermatitis  ÀÌ¿µº¹(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 10:35~11:00 Practical laboratory tests in your clinic  ÇÑÅ¿µ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:00~11:20 What's new in researches of atopic dermatitis?  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
È޽Ġ10-02 ±×·£µåº¼·ë 11:20~11:40 Break time  () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 11:40~12:20 Recognizing the multi-dimensional impact of atopic dermatitis patients and systemic comorbidities  Jonathan Silverberg(George Washington University School of Medicine and Health Sciences, USA) 
½Ä»ç 10-02 ±×·£µåº¼·ë 12:20~13:10   () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:10~13:20 Mycosis fungoides Found in Patients with Atopic Dermatitis Refractory to Dupilumab  ±¹Çüµ·(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:20~13:30 New On of Alcohol Flushing in Patients with Atopic Dermatitis Treated with Dupilumab: Is It an Underrecognized Adverse Event?  ½Éµ¿Çö(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:30~13:40 Preventive effects of topical diquafosol on dupilumab-associated conjunctivitis in atopic dermatitis: an open-label prospective study  ÀÌÁø¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:40~13:50 Effects of Gamma-Linolenic Acid Adjuvant Therapy in Patients with Atopic Dermatitis: A Survey Study  µµÁöÀ±(Ä«Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 13:50~14:30 Optimal use of Janus kinase inhibitors and dupilumab for atopic dermatitis based on the current evidence  Masahiro Kamata(Teikyo University, Japan) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:30~14:55 Update in pediatric atopic dermatitis  Àå¿ëÇö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 14:55~15:20 Treatments of pediatric atopic dermatitis : Face to unmet needs  °íÇöâ(ºÎ»êÀÇ´ë) 
È޽Ġ10-02 ±×·£µåº¼·ë 15:20~15:40 Break time  () 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 15:40~16:20 Treat to target in atopic dermatitis : Significance and strategy  Yoko Kataoka(Osaka Habikino Medical Center, Japan) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:20~16:45 Biologics & small molecules treatment of atopic dermatitis patients : How and when?  ½Å¹Î°æ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10-02 ±×·£µåº¼·ë 16:45~17:10 Upcoming therapies of atopic dermatitis compared with psoriasis : What's in the pipeline?  ¹èÀ¯ÀÎ(ÇѸ²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ Á¦22Â÷ Çмú´ëȸ : 2022-10-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ÀÏÂ÷ÀÇ·á±â°ü °¨¿°º´ ´ëÀÀ ¿Â¶óÀÎ ¿¬¼ö±³À°(Á¦4Â÷) : 2022-10-04
´ÙÀ½±Û ´ëÇÑÅëÁõÇÐȸ ºÎ¿ï°æÁöȸ Áý´ãȸ : 2022-10-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
60 ºÎ»ê 2018³â ´ëÇѼÒÈ­±â¿¬°üÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2018-08-18 0 675 2018-07-28
59 ¼­¿ï ´ëÇÑ»êºÎÀΰúÀÇ»çȸ&Çѱ¹¹ß»ý»ý¹°ÇÐȸ Joint Symposium : 2018-08-18 0 1,080 2018-07-28
58 ¼­¿ï ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18 0 705 2018-07-28
57 ¼­¿ï ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18 0 834 2018-07-28
56 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17 0 857 2018-07-28
55 °­¿ø ´ëÇѽÉÀåÇÐȸ Ç÷°ü¿¬±¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö : 2018-08-17 0 1,286 2018-07-28
54 ¼­¿ï Á߾Ӵ뺴¿ø »êºÎÀΰú žÆÃÊÀ½ÆÄ ¿¬¼Ó°­Á : 2018-08-16 0 659 2018-07-28
53 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À°(ÈĵÎÁúȯ) : 2018-08-16 0 728 2018-07-28
52 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] °Ç°­º¸Çè ¼ö°¡°áÁ¤ : 2018-08-16 0 865 2018-07-28
51 ¼­¿ï Çѱ¹¿ªÇÐȸ Biomarker ¸¦ ÀÌ¿ëÇÑ ¿¬±¸ ¼³°è¿Í ºÐ¼® : 2018-08-14 0 1,276 2018-07-28
50 ¼­¿ï Á¦240ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ : 2018-08-14 0 423 2018-07-28
49 ¼­¿ï Çѱ¹¿ªÇÐȸ MR ±â¹Ý À¯Àüü ¿ªÇבּ¸¿Í °ø°ø°Ç°­ÀÚ·á ±â¹Ý Outcome research : 2018-08-13 0 646 2018-07-28
48 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø 2018 Catholic Orthopedic Symposium II - Foot & Ankle, Hip, Knee - : 2018-08-12 0 1,100 2018-07-28
47 ¼­¿ï 2018 ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2018-08-12 0 538 2018-07-28
46 ¼­¿ï 2018 Á¦ 2ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ ±¹Á¦½ÉÆ÷Áö¾ö : 2018-08-11 0 1,421 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷